Generation of induced pluripotent stem cells (IRMBi001-A) from an Alzheimer's disease patient carrying a G217D mutation in the PSEN1 gene.


Journal

Stem cell research
ISSN: 1876-7753
Titre abrégé: Stem Cell Res
Pays: England
ID NLM: 101316957

Informations de publication

Date de publication:
01 2019
Historique:
received: 24 10 2018
revised: 19 12 2018
accepted: 31 12 2018
pubmed: 25 1 2019
medline: 7 8 2019
entrez: 25 1 2019
Statut: ppublish

Résumé

Induced pluripotent stem cells (iPSC) were generated from skin fibroblasts obtained from a 50 year-old patient suffering from Alzheimer's disease and carrying a G217D causal mutation on presenilin 1 (PSEN1). iPSCs were obtained following reprogramming using the integration-free Sendai Virus system which allows expression of the Yamanaka factors. Verification of their pluripotency was achieved by demonstrating the expression of pluripotency markers and their differentiation potential into the three primary germ layers. iPS cells carry the patient G217D mutation and present a normal karyotype. The reported PS1-G217D iPSC line may be used to model and study human AD pathology in vitro.

Identifiants

pubmed: 30677723
pii: S1873-5061(18)30316-7
doi: 10.1016/j.scr.2018.101381
pii:
doi:

Substances chimiques

PSEN1 protein, human 0
Presenilin-1 0

Types de publication

Journal Article

Langues

eng

Pagination

101381

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.

Auteurs

L Auboyer (L)

Institute for Regenerative Medicine and Biotherapy (IRMB), Montpellier, France; Université de Montpellier, UM, 163 Rue Auguste Broussonnet, 34090 Montpellier, France.

C Monzo (C)

Institute for Regenerative Medicine and Biotherapy (IRMB), Montpellier, France; Université de Montpellier, UM, 163 Rue Auguste Broussonnet, 34090 Montpellier, France.

D Wallon (D)

Normandie Univ, UNIROUEN, Inserm U1245, Rouen University Hospital, Department of Neurology and CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, F 76000 Rouen, France.

A Rovelet-Lecrux (A)

Normandie Univ, UNIROUEN, Inserm U1245, Rouen University Hospital, Department of Genetics and CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, F 76000 Rouen, France.

A Gabelle (A)

Institute for Regenerative Medicine and Biotherapy (IRMB), Montpellier, France; Hopital St Eloi, CHU Montpellier, 80 rue augustin Fliche, 30295 Montpellier, France; Université de Montpellier, UM, 163 Rue Auguste Broussonnet, 34090 Montpellier, France.

I Gazagne (I)

Hopital St Eloi, CHU Montpellier, 80 rue augustin Fliche, 30295 Montpellier, France.

V Cacheux (V)

Hopital St Eloi, CHU Montpellier, 80 rue augustin Fliche, 30295 Montpellier, France.

S Lehmann (S)

Institute for Regenerative Medicine and Biotherapy (IRMB), Montpellier, France; Hopital St Eloi, CHU Montpellier, 80 rue augustin Fliche, 30295 Montpellier, France; Université de Montpellier, UM, 163 Rue Auguste Broussonnet, 34090 Montpellier, France.

C Crozet (C)

Institute for Regenerative Medicine and Biotherapy (IRMB), Montpellier, France; Hopital St Eloi, CHU Montpellier, 80 rue augustin Fliche, 30295 Montpellier, France; Université de Montpellier, UM, 163 Rue Auguste Broussonnet, 34090 Montpellier, France. Electronic address: carole.crozet@inserm.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH